🟢 Cybin is trading 5.19% up in pre-market after HLP003 12-month efficacy data

Cybin is trading 5.19% higher at $13.24 after 12-month HLP003 efficacy data in major depressive disorder were presented at Psychiatry Congress 2026.

• The data informed the company’s ongoing Phase 3 program.
• Investors may also be reacting to upcoming Phase 3 milestones, with topline data expected during Q4 2026.
• No volume figures or separate overnight filing were identified.